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Abstract
Objectives The purpose of this study is to evaluate the predictive value of the amount of fibroglandular tissue (FGT) and
background parenchymal enhancement (BPE), measured at baseline on breast MRI, for breast cancer development and risk of
false-positive findings in women at increased risk for breast cancer.
Methods Negative baseline MRI scans of 1533 women participating in a screening program for women at increased risk for
breast cancer between January 1, 2003, and January 1, 2014, were selected. Automated tools based on deep learning were used to
obtain quantitative measures of FGT and BPE. Logistic regression using forward selection was used to assess relationships
between FGT, BPE, cancer detection, false-positive recall, and false-positive biopsy.
Results Sixty cancers were detected in follow-up. FGT was only associated to short-term cancer risk; BPE was not associated
with cancer risk. High FGTand BPE did lead to more false-positive recalls at baseline (OR 1.259, p = 0.050, and OR 1.475, p =
0.003) and to more frequent false-positive biopsies at baseline (OR 1.315, p = 0.049, and OR 1.807, p = 0.002), but were not
predictive for false-positive findings in subsequent screening rounds.
Conclusions FGT and BPE, measured on baseline MRI, are not predictive for overall breast cancer development in women at
increased risk. High FGT and BPE lead to more false-positive findings at baseline.
Key Points
• Amount of fibroglandular tissue is only predictive for short-term breast cancer risk in women at increased risk.
• Background parenchymal enhancement measured on baseline MRI is not predictive for breast cancer development in women at
increased risk.
• High amount of fibroglandular tissue and background parenchymal enhancement lead to more false-positive findings at
baseline MRI.
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Abbreviations
ACR American College of Radiology
BD Breast density
BPE Background parenchymal enhancement
CI Confidence interval
DCIS Ductal carcinoma in situ
FGT Fibroglandular tissue
FPB False-positive biopsy
FPR False-positive recall
IQR Interquartile range
MRI Magnetic resonance imaging
NME Non-mass enhancement
OR Odds ratio
ROC Receiver operating characteristic
RRSO Risk-reducing salpingo-oophorectomy
Introduction
Women at increased risk of breast cancer (≥ 20–25% lifetime
risk) are eligible for intensified screening programs, including
a yearly breast magnetic resonance imaging (MRI) study.
Depending on the underlying risk factors, MRIs may be per-
formed on an annual basis from the age of 25 (in BRCA mu-
tation carriers) [1, 2]. Women with a hereditary germline mu-
tation and women with a history of radiation therapy to the
chest at a young age are eligible to these programs. For other
women, risk-prediction tools are used to determine whether
women are at increased risk and thus eligible for MRI screen-
ing. The current risk-prediction tools rely mainly on personal
factors, such as family history, age, and race [3, 4]. However,
recent studies show that additional independent risk factors,
including imaging biomarkers, might increase the predictive
power of risk prediction.
Mammographic breast density (BD), for example, corre-
lates to breast cancer risk in the general female population
and in BRCAmutation carriers [5, 6]. Consequently, a number
of studies recommend adding BD to the available risk predic-
tion tools [7–10].
The increased use of breast MRI allows for evaluation of
additional risk factors to improve current risk prediction tools.
Recent publications indicate that the amount of fibroglandular
tissue (FGT) and/or background parenchymal enhancement
(BPE)measured on breastMRImay be useful to predict breast
cancer risk in women undergoing breast MRI [11–13], al-
though results have to be interpreted with caution [14].
While in breast MRI all normal FGT enhances after con-
trast injection, the strength and speed of enhancement is de-
pendent on variations in hormone levels, as determined by
menstrual cycle phase, menopausal status, tamoxifen therapy,
and hormone replacement therapy [15–17]. Studies of King
et al and Dontchos et al [11, 12] showed that higher amounts
of BPE in the contralateral breast increase the risk of breast
cancer diagnosis. Their results thus suggest that BPE might be
used for the prediction of breast cancer risk. Unfortunately,
both studies evaluated BPE at time of breast cancer detection
and are therefore unable to document its predictive value for
future breast cancer occurrence.
A further problem is that visual rating of BPE on a four-
point scale (minimal < 25%, mild 25–50%, moderate 50–
75%, and marked 75–100%), as used in studies so far, suffers
from high interrater variability [18]. This limits its value for
risk prediction. Analogue to systems currently in use to auto-
matically estimate BD on digital mammograms, automated
tools to assess FGT and BPE may reduce interrater variability
and possibly provide more robust parameters for risk
stratification.
The purpose of this study is to study whether FGT and
BPE, as computed on a cancer-free baseline MRI scan using
an automated tool, are predictors of future breast cancer in a
breast MRI screening program. Furthermore, we evaluate
whether FGT and BPE predict false-positive findings.
Materials and methods
This retrospective cohort study was approved by our local
institutional review board, and the requirement for informed
consent was waived.
Screening program
The breast cancer screening program for women with a life-
time risk of ≥ 20–25% at our institution consists of annual
breast MRI and mammography [1, 19]. In BRCA mutation
carriers, the screening regimen starts with breast MRI only
at age 25. Mammography is added from age 30. Others start
screening with both modalities at age 35 or 40, depending on
the age at which relatives developed breast cancer. The first
MRI scan performed for screening is hereafter referred to as
Bbaseline^ MRI.
Case selection
The local database was searched to identify all patients who
underwent breast MRI screening between January 1, 2003,
and January 1, 2014. The case selection process is presented
in Fig. 1. Women of any age were included when they
underwent at least two breast MRI examinations for screening
in this period. We recorded for each patient whether a BRCA
mutation was present and whether and when a risk-reducing
salpingo-oophorectomy (RRSO) was performed. Women in
whom a cancer was detected at baseline MRI or within
6 months thereafter, women with a prior history of breast
cancer, and women in whom automated assessment of BPE
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failed were excluded. We did not exclude women who had a
false-positive finding in the first round of screening.
Ground truth
Normal or benign screening examinations were confirmed by
at least one year of clinical follow-up and regarded as true
negative when no cancer was detected before the subsequent
screening examination. When no biopsy was indicated at
short-term follow-up, at least one year of clinical follow-up
was required to confirm benignity. Biopsied lesions were
identified by a cross-computer search with our pathology re-
cords. We subsequently analyzed if the biopsy was performed
based on screening findings or for other reasons (e.g.,
symptoms).
Image acquisition
MRI protocols varied over time [20]. Dynamic contrast-
enhanced breast MRI acquisitions were performed on either
a 1.5- or 3-T Siemens scanner using a dedicated bilateral
breast coil. Patients were placed in prone position. A trans-
verse or coronal three-dimensional T1-weighted gradient-
echo dynamic sequence was performed before contrast agent
administration followed by four or five post-contrast se-
quences. The first time point was acquired before intravenous
agent injection and the following time points after contrast
agent injection. The gadolinium chelates were administered
at a dose of 0.1 mmol/kg or 0.2 mmol/kg using a power in-
jector (Medrad), followed by a saline flush.
Imaging interpretation
Automatic tools were used to objectively calculate percent-
ages of FGT and BPE on breast MRI volumes. Breast and
FGT were segmented on native T1-weighted pre-contrast ac-
quisitions using a deep-learning-based method as described
and validated in [20]. The fraction of FGT was calculated as
the segmented volume of FGT divided by the total breast
volume. BPE relative enhancement values were computed
using the pre-contrast and the first post-contrast T1-weighted
acquisition after motion correction [21], according to the ACR
guidelines [22, 23]. The fraction of BPE is expressed relative
to the volume of FGT, where an FGT voxel is considered to
enhance if it has a relative enhancement value higher than
10%, which correlates best to radiologist rates according to
Dalmis et al [24]. Figure 2 shows an example of automated
computations of FGT and BPE. Final FGTand BPE measure-
ments were the result of averaging over the two breasts of each
woman. To verify whether correlations change when investi-
gating different cut-off values, we performed the same analy-
ses on 20%, 30%, 40%, and 50% relative enhancement values
(Supplementary Table 2).
Data analysis
Womenwho developed cancer were identified by linkage of our
data to the Netherlands Comprehensive Cancer Organisation.
False-positive MRI examinations were defined as examinations
that led to recall in women in whom no breast cancer was
detected. False-positive recalls (FPR) include all women who
were recalled (with or without performance of biopsy). False-
positive biopsies (FPB) only include women for whom the re-
call led to biopsy. We separated FPR and FPB in first rounds
from those that occurred in subsequent screening rounds.
To investigate the influence of time between the baseline
scan and cancer development, we performed a subgroup anal-
ysis in patients who developed breast cancer within 2 years
after the baseline MRI scan.
Statistical analysis
Incomplete data was assumed to be missing at random and
was excluded. Descriptive statistics were prepared with the
use of contingency-table analyses for categorical data and
Fisher’s exact tests. The 95% confidence intervals (95% CI)
for proportions were estimated using the Z test for single pro-
portions. Continuous data were compared with the Student’s t
test or Pearson correlation coefficient (r) when normally dis-
tributed; otherwise, Mann-Whitney U tests were used.
Bootstrapping (N = 1000) was used to calculate 95% CI. To
increase statistical power, FGT and BPE were dichotomized
into two categories based on the optimal categories in ROC
analysis (0–50th percentile and 50–100th percentile). A
Fig. 1 Flow diagram of the case selection procedure. BPE, background
parenchymal enhancement; FGT, amount of fibroglandular tissue
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binary logistic regression model was constructed to find inde-
pendent predictors for breast cancer or false positives.
Separate and combined models were performed for FGT and
BPE. Inclusion of variables in the model was based on
existing knowledge of risk factors for breast cancer and/or
false positives (covariates: age and BRCA status). Non-linear
effects were evaluated using Box-Tidwell tests and when
needed transformations were performed. The value of predic-
tors was assessed by using forward feature selection (using a
liberal probability-to-enter of 0.1). Interactions between pre-
dictors were evaluated in the final models by including inter-
action terms along with the main-effect terms. The final model
was bootstrapped (N = 1000). Shrinkage using the heuristic
method was applied to account for over-optimism [25].
Odds ratios (OR) were used to report on the relative odds of
occurrence of the outcome (future cancer, or false-positive
result), where OR = 1, the predictor does not affect odds of
outcome; OR > 1, the predictor is associated with higher odds
of outcome; and OR < 1, the predictor is associated with lower
odds of outcome. All statistical tests were two-sided. p ≤ 0.05
was considered significant. All statistics were performed in
SPSS (v.22, SPSS Inc.).
Results
Population
The final analysis evaluated baseline breast MRI scans of
1533 women, including 573 (37.4%) BRCA mutation carriers
(Supplementary Table 1). Patient selection and exclusion are
shown in Fig. 1. The median age at baseline was 41 years
(37 years for BRCAmutation carriers and 44 years for others).
In 60 (3.9%) women, cancer was identified after a negative
baseline scan. Forty-five (75%) cancers were screen-detected
cancers, six (10%) were interval cancers, and nine (15%) were
detected in prophylactic mastectomies. Forty-three (71.7%)
cancers were invasive and 17 (28.3%) were ductal carcinoma
in situ (DCIS) only. The median time between the negative
baseline scan and cancer detection was 3 years (two in BRCA
patients, three in others). Of the 573 BRCA mutation carriers,
103 (18%) women had a RRSO prior to the first screening
round, while 227 underwent RRSO after the first screening
round.
Three hundred thirty-seven (22.0%) women had a false-
positive recall. Seventy-three (21.7%) of these women were
recalled based upon mammography findings. Two hundred
sixty-four (78.3%) women had at least one false-positive re-
call based on the MRI exam (total, 286 recalls on MRI), and
203 (13.2%) women had at least one false-positive biopsy due
to MRI findings (total, 217 biopsies). Median FGT measured
on MRI was 12.7% (interquartile range (IQR), 18.9%), and
median BPEwas 67.7% (IQR, 27.6%). Tables 1, 2, and 3 have
a more detailed presentation of the population characteristics.
In univariate analysis, a significant association between
FGT and BRCA status was found in both percentages (p =
0.001) and the dichotomous scores (p < 0.001). BRCA muta-
tion carriers had lower FGT scores than others. The BRCA
mutation carriers had a lower age at the baseline scan (median
age of 37 for BRCA mutation carriers versus 44 for others,
p < 0.001). A similar association was found between the per-
centage of BPE and BRCA status (p = 0.005), as BRCA muta-
tion carriers had significantly lower BPE scores.When dichot-
omizing BPE, this remained significant (p = 0.020). FGT and
BPE were negatively correlated to age (r = − 0.289 and
r = − 0.129, p < 0.001), also when using dichotomous values
(p ≤ 0.007). In BRCA mutation carriers, coefficients were
r = − 0.418 (p < 0.001) and r = − 0.132 (p = 0.002), respec-
tively, and in women without a BRCA mutation, r = − 0.307
(p < 0.001) and r = − 0.152 (p < 0.001). FGT and BPE were
not correlated (p = 0.879). Plots of the univariate analysis are
presented in Figs. 3 and 4. In BRCA mutation carriers, BPE
was not associated with a history of RRSO (p = 0.886,
Table 2).
Cancer prediction models
In univariate analysis, FGT was not associated with breast
cancer for both discrete (p = 0.768) and dichotomous values
(p = 0.511). In regression analysis, FGTwas not considered an
independent risk factor for breast cancer; only BRCA status
was (OR, 3.615; p = 0.001). Likewise, percentages and di-
chotomized BPE scores of the baseline MRI scan were not
associated with breast cancer (p = 0.625 and p = 0.236). In
regression analysis, adjusting for the only significant risk fac-
tor (BRCA status), BPE was also no significant predictor of
cancer (p = 0.112). When evaluating both FGT and BPE, both
were not significantly associated with breast cancer risk (p =
0.824 and p = 0.112). Also in the subgroup of the BRCA and
non-BRCA mutation carriers only, BPE and FGT were not
associated to breast cancer.
The subgroup analysis on cancers developed in the first
two years after baseline MRI scan included 17 cancers and a
total of 1499 baseline MRI scans. In univariate and multivar-
iate analyses, continuous BPEwas still not associated to breast
cancer (p = 0.302), but FGT was (p = 0.030). Dichotomizing
BPE (p = 0.234) and FGT (p = 0.012) did not change results.
In regression analysis, FGT was associated to breast cancer
(p = 0.036), but BPE was not (p = 0.137). Details of predictors
can be found in Table 4.
FPR models
When investigating the first-round results alone (diagnos-
tic model), both FGT and BPE were correlated to higher
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FPR (OR, 1.259; p = 0.050, and OR, 1.475; p = 0.003, re-
spectively). For subsequent rounds (prognostic model),
higher FGT at baseline was still significantly related to
higher FPR in both continuous and dichotomized values
Table 1 Baseline patient
characteristics Total cohort
(N = 1533)
Developed cancer
Yes (N = 60) No (N = 1473)
Age in years; median$ (IQR) 41 (17.0) 40 (13.0) 42 (17.0)
BRCA mutation carriers; N (fraction*) 573, 0.37 41, 0.68 532, 0.36
FGT in percentage; median$ (IQR) 12.7 (18.9) 11.6 (19.8) 12.7 (18.7)
BPE in percentage; median$ (IQR) 67.7 (27.6) 71.3 (30.4) 67.6 (27.6)
Cancer; N (fraction*) 60, 0.04 60 (N/A) N/A
Age at cancer detection; median$ (IQR) 42 (15.0) 42 (15.0) N/A
False-positive recall overall; N (fraction*) 337, 0.22 19, 0.32 318, 0.22
Age at recall; median$ (IQR) 42 (15.0) 40 (18.0) 42 (15.0)
False-positive recall MRI; N (fraction*) 264, 0.17 16, 0.27 248, 0.17
Age at recall; median$ (IQR) 40 (15.0) 39 (16.8) 40 (15.0)
False-positive biopsy overall; N (fraction*) 221, 0.14 12, 0.20 209, 0.14
Age at biopsy; median$ (IQR) 41 (14.5) 39 (16.5) 41 (14.5)
False-positive biopsy MRI; N (fraction*) 203, 0.13 11, 0.18 192, 0.13
Age at biopsy; median$ (IQR) 40 (15.0) 38 (18.0) 40 (15.0)
RRSO; N (fraction*) 103, 0.07 5, 0.08 98, 0.07
N/A not applicable, BPE background parenchymal enhancement, FGT amount of fibroglandular tissue, IQR the
difference between the 75th and 25th percentiles, RRSO risk-reducing salpingo-oophorectomy
* Fraction of positive cases compared to the complete cohort
$ Tested on normality using the Kolmogorov-Smirnov test
Fig. 2 An example of the steps of
the automated tool to determine
the amount of fibroglandular
tissue (FGT) and background pa-
renchymal enhancement (BPE).
First, the original image (a), then
the breasts and parenchymal tis-
sue (b) are segmented, and finally,
relative enhancement values are
computed for the segmented FGT
volumes (c). BPE values are ex-
tracted from the enhancing voxels
within the parenchymal tissue,
based on these relative enhance-
ment values
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(p ≤ 0.029). BPE, however, was not related to FPR
(p ≥ 0.818) in univariate analysis. In regression analysis,
only age remained as related factor to FPR in follow-up
(OR, 0.955, p = 0.001; Table 5).
FPB models
When only investigating the first round (diagnostic model),
both FGT and BPE were correlated to higher FPB (OR, 1.315
Table 3 Baseline characteristics
of others at increased risk Total cohort
(N = 960)
Developed cancer
Yes (N = 19) No (N = 941)
Age in years; median$ (IQR) 44 (15) 40 (11) 44 (15)
FGT in percentage; median$ (IQR) 14.9 (20.7) 20.8 (20.5) 14.8 (20.6)
BPE in percentage; median$ (IQR) 69.0 (27.6) 73.4 (29.1) 69.0 (27.6)
Cancer; N (fraction*) 19, 0.02 19, 1.00 N/A
Age at cancer detection; median$ (IQR) 43 (16) 43 (16) N/A
False-positive recall overall; N (fraction*) 219, 0.23 7, 0.37 212, 0.23
Age at recall; median$ (IQR) 43 (14) 46 (15) 43 (14)
False-positive recall MRI; N (fraction*) 167, 0.23 6, 0.32 161, 0.17
Age at recall; median$ (IQR) 42 (15) 47.5 (17.8) 42 (14)
False-positive biopsy overall; N (fraction*) 141, 0.15 5, 0.26 136, 0.14
Age at biopsy; median$ (IQR) 43 (14) 46 (10) 43 (14)
False-positive biopsy MRI; N (fraction*) 131, 0.14 4, 0.21 127, 0.13
Age at biopsy; median$ (IQR) 42 (14) 47.5 (12.5) 42 (14)
RRSO; N (fraction*) 0, 0.00 0, 0.00 0, 0.00
N/A not applicable, BPE background parenchymal enhancement, FGT amount of fibroglandular tissue, IQR the
difference between the 75th and 25th percentiles, RRSO risk-reducing salpingo-oophorectomy
* Fraction of positive cases
$ Tested on normality using the Kolmogorov-Smirnov test
Table 2 Baseline characteristics
of BRCA mutation carriers Total cohort
(N = 573)
Developed cancer
Yes (N = 41) No (N = 532)
Age in years; median$ (IQR) 37 (17) 41 (14.5) 37 (18)
FGT in percentage; median$ (IQR) 9.3 (14.5) 10.7 (16.7) 9.3 (14.5)
BPE in percentage; median$ (IQR) 65.6 (26.7) 71.2 (33.3) 65.1 (26.1)
Cancer; N (fraction*) 41, 0.07 41, 1.00 0, 0.00
Age at cancer detection; median$ (IQR) 42 (14.5) 42 (14.5) N/A
False-positive recall overall; N (fraction*) 118, 0.21 12, 0.29 106, 0.20
Age at recall; median$ (IQR) 38.5 (15) 38 (19.5) 39 (14.3)
False-positive recall MRI; N (fraction*) 97, 0.17 10, 0.24 87, 0.16
Age at recall; median$ (IQR) 38 (14.5) 38 (18.75) 39 (14)
False-positive biopsy overall; N (fraction*) 80, 0.14 7, 0.17 73, 0.14
Age at biopsy; median$ (IQR) 38 (14) 34 (11) 39 (14.5)
False-positive biopsy MRI; N (fraction*) 72, 0.13 7, 0.17 65, 0.12
Age at biopsy; median$ (IQR) 38 (15.3) 34 (11) 38 (15.5)
RRSO; N (fraction*) 103, 0.18 5, 0.12 98, 0.18
N/A not applicable, BPE background parenchymal enhancement, FGT amount of fibroglandular tissue, IQR the
difference between the 75th and 25th percentiles, RRSO risk-reducing salpingo-oophorectomy
* Fraction of positive cases
$ Tested on normality using the Kolmogorov-Smirnov test
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Fig. 3 Distribution of the amount of fibroglandular tissue (FGT) for
women with a BRCA mutation and women without a BRCA mutation.
In a, box plots show the lowest and highest FGT values (outermost
horizontal lines), median FGT (central horizontal line), and interquartile
range (top and bottom borders of the box) for breast cancer (no/yes).
Scatter plots show the association of FGT to breast cancer occurrence
(no/yes) and age at baseline MRI (b). In c, boxplots are shown for
false-positive recall occurrence (no/yes), and in d, scatterplots show the
association of FGT to false-positive recall occurrence
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Fig. 4 Distribution of the background parenchymal enhancement (BPE)
for women with a BRCAmutation and women without a BRCAmutation.
In a, box plots show the lowest and highest BPE values (outermost hor-
izontal lines), median BPE (central horizontal line), and interquartile
range (top and bottom borders of the box) for breast cancer (no/yes).
Scatter plots show the association of BPE to breast cancer occurrence
(no/yes) and age at baseline MRI (b). In c, boxplots are shown for
false-positive recall occurrence (no/yes), and in d, scatterplots show the
association of BPE to false-positive recall occurrence
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(p = 0.049) and OR, 1.807 (p = 0.002), respectively).When
excluding the FPB in the first round (prognostic model),
FGT and BPE were both not related to FPB (p ≥ 0.066) in
univariate analysis. Regression analysis showed that age was
negatively related to FPB in follow-up (p = 0.001, Table 5).
No interaction terms were found to be significant in any of
the prediction models. In addition, changing levels of BPE
cutoffs did not change any of the conclusions for both the
cancer- and false-positive prediction models (Supplementary
Tables 2 and 3).
Discussion
The purpose of this study was to investigate the predictive
value of the amount of fibroglandular tissue (FGT) and back-
ground parenchymal enhancement (BPE) in predicting breast
cancer risk in a population at increased risk of developing
breast cancer. Additionally, the effect of FGT and BPE on
false-positive recalls and biopsies was investigated. Our re-
sults show that neither FGT nor BPE at baseline was
associated with the overall risk of developing breast cancer.
However, in subgroup analysis only evaluating the cancers
detected in the first 2 years after the baseline MRI scan, we
found an association with FGT. Both higher FGTand BPE did
lead to higher odds ratios for false-positive findings in the
baseline examination.We did not observe any predictive value
of FGT or BPE for FPR or FPB in subsequent screening
rounds.
It has already been well established that mammographic
breast density (BD) impairs mammographic sensitivity [26].
In an average-risk population, BD is also known to correlate
with breast cancer risk [5]. In line with the studies from
Dontchos et al [11] and Passaperuma et al [27] who reported
that neither mammographic BD nor FGT on MRI were pre-
dictive of breast cancer risk in women at increased risk, we did
not observe an overall correlation between FGT and the de-
velopment of breast cancer in our high-risk cohort. However,
Mitchell et al [6] reported contradictory results. In their study,
it was suggested that high BD in BRCA mutation carriers
increased the risk of breast cancer, with a relative risk similar
to that observed in the general population. In our subgroup
Table 4 Regression coefficients and odds ratios for the prognostic cancer prediction model
Model Predictor p value Included in
final model
β OR Shrinkage
factor(95% CI) (95% CI)
Overall population
Cancer-FGT BRCA* < 0.001 x 1.285 (0.762 to 1.872) 3.615 (2.143 to 6.501) 0.96
Age 0.930 –
FGT 0.511 –
Cancer-BPE BRCA* < 0.001 x 1.285 (0.769 to 1.875) 3.615 (2.158 to 6.521) 0.96
Age 0.930 –
BPE 0.236 –
Subgroup BRCA
Cancer-FGT Age 0.330 – N/A
FGT 0.936 –
Cancer-BPE Age 0.330 – N/A
BPE 0.106 –
Subgroup non-BRCA
Cancer-FGT Age 0.126 – N/A
FGT 0.621 –
Cancer-BPE Age 0.126 – N/A
BPE 0.641 –
Subgroup cancer within 2 years after baseline MRI scan
Cancer-FGT BRCA* 0.003 x 1.707 (0.696 to 15.557)
− 1.078 (− 15.032 to − 0.076)
5.512 (2.006 to 5.706 · 106)
0.340 (2.963 · 10−7 to 0.927)
0.90
Age 0.507 –
FGT 0.036 x
Cancer-BPE BRCA* x 1.961 (0.928 to 16.418) 7.106 (2.529 to 1.350 · 107) 0.93
Age 0.189 –
BPE 0.137 –
For every model, different shrinkage factors were used; shrunk β and OR are presented
β standardized coefficients, OR odds ratio, CI confidence interval, FGT amount of fibroglandular tissue, BPE background parenchymal enhancement,
N/A not applicable
*BRCA = 0 is reference category
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analysis, we found that FGT might be associated with early
cancer development, and as FGT and BPE may change due to
normal hormonal changes, it might be logical that the predic-
tive potential in the longer run is relatively limited in this
generally young population. However, as this analysis includ-
ed small cancer numbers and results showed extremely large
confidence intervals, these results need to be evaluated with
caution. It should be noted that the differences between those
studies and our findingsmay at least partly be explained by the
automated volumetric FGT estimation in our study, which
provides a different representation of the FGT than visually
inspected BD in mammography, albeit previous studies
showed a clear correlation between these measurements
[28], and the applied method proved to be robust to variations
in MRI acquisitions and breast density categories [19]. It may
also be related to the limited sample size in our study and other
studies published thus far.
Current clinical practice is shifting towards personalized
screening, making risk prediction tools increasingly impor-
tant. Recent case-control studies have shown that BPE might
Table 5 Regression coefficients and odds ratios for the effect on current and subsequent MRI scans on false-positive findings
Model Predictor p value Included in
final model
β OR Shrinkage
factor(95% CI) (95% CI)
Diagnostic model for false-positive findings (current MRI scans)
FPR-FGT BRCA 0.771 –
Age 0.167 –
FGT* 0.050 x 0.230 (0.012 to 0.451) 1.259 (1.012 to 1.569) 0.74
FPR-BPE BRCA 0.612 –
Age 0.102 –
BPE* 0.003 x 0.389 (0.120 to 0.666) 1.475 (1.128 to 1.946) 0.87
FPR-FGTand BPE BRCA 0.894 –
Age 0.229 –
FGT* 0.072 x 0.251 (− 0.013 to 0.535) 1.285 (0.987 to 1.707) 0.83
BPE* 0.005 x 0.366 (0.111 to 0.625) 1.442 (1.118 to 1.868)
FPB-FGT BRCA 0.350 –
Age 0.496 –
FGT* 0.049 x 0.274 (0.022 to 0.568) 1.315 (1.022 to 1.765) 0.74
FPB-BPE BRCA 0.269 –
Age 0.362 –
BPE* 0.002 x 0.592 (0.253 to 0.957) 1.807 (1.288 to 2.605) 0.91
FPB-FGTand BPE BRCA 0.453 –
Age 0.651 –
FGT* 0.064 x 0.312 (− 0.012 to 0.677) 1.367 (0.988 to 1.968) 0.87
BPE* 0.002 x 0.559 (0.218 to 0.911) 1.750 (1.243 to 2.487)
Prognostic model for false-positive findings
FPR-FGT BRCA 0.773 – − 0.047 (− 0.069 to − 0.026) 0.955 (0.933 to 0.975) 0.95
Age 0.001 x
FGT 0.224 –
FPR-BPE BRCA 0.773 – − 0.047 (− 0.069 to − 0.026) 0.955 (0.933 to 0.975) 0.95
Age 0.001 x
BPE 0.932 –
FPB-FGT BRCA 0.892 – − 0.051 (− 0.081 to − 0.026) 0.951 (0.922 to 0.974) 0.94
Age 0.001 x
FGT 0.557 –
FPB-BPE BRCA 0.892 – − 0.051 (− 0.081 to − 0.026) 0.951 (0.922 to 0.974) 0.94
Age 0.001 x
BPE 0.572 –
For every model, different shrinkage factors were used; shrunk β and OR are presented
β standardized coefficients, OR odds ratio, CI confidence interval, FGT amount of fibroglandular tissue, BPE background parenchymal enhancement
* FGT and BPE = low is reference category
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be predictive of breast cancer risk [11, 12], although contra-
dictory results exist for non-high-risk women [29]. However,
in these studies, the BPE scores of the healthy breast (partly
for [11]) in breast cancer patients were compared to BPE
scores in healthy controls. The current study, in which BPE
before cancer development is evaluated in actual patients,
suggests that BPE is not predictive for breast cancer in women
at increased risk. A possible explanation for this is that in case-
control studies, BPE in cancer patients might have been af-
fected by the presence of breast cancer. Consequently, further
research into the biological basis and modifying factors of
BPE is needed. Alternatively, our results might point to a
different carcinogenesis in women at increased risk.
Evidence suggests that BPE correlates negatively with age
and increases with hormonal activity [30–32]. Interestingly,
our results showed that BRCA mutation carriers had signifi-
cantly lower FGT and BPE values compared to women with-
out a BRCA mutation, while the age of BRCA mutation car-
riers was significantly lower than that of women without
BRCA mutation. This counterintuitive result may be due to
differences in the effect of hormones on FGT in women with
and without BRCA mutation [33]. The fact that we did not
observe a difference in BPE between the BRCA mutation car-
riers who did and did not undergo a RRSO before the baseline
MRI also points in this direction. Nevertheless, prior research
showed that RRSOmay still reduce both BPE and FGT values
[34], and therefore, our results need to be interpreted with
caution as they might also be explained by the relatively low
number of women who underwent RRSO in our study. It
should be noted that the performance of RRSO in BRCA mu-
tation carriers after the baseline examination may have had
impact on the predictive value of FGT and BPE in these
women.
Women with high BPE scores had a 1.5 times higher
chance to get a FPR, and 1.8 times higher chance to get a
FPB in the first screening round. This is in line with previous
studies, describing that more focal, regional, or asymmetric
BPE was associated with a higher likelihood of BI-RADS 3
assessment in the screening setting [35]. Giess et al stated that,
in the latter case, it may be hard to distinguish BPE from non-
mass enhancement (NME) [36]. Consequently, when the en-
hancement pattern is interpreted as NME, the reporting radi-
ologist has to consider the possibility of malignancy; thus,
chances on false positives increase. DeMartini et al [37] also
reported that higher amounts of BPE were associated with
higher rates of abnormal interpretation. Brennan et al reported
that moderate and marked BPE are associated with signifi-
cantly higher MR imaging-guided core biopsy cancelation
rates compared to minimal or mild BPE [38]. However, the
even stronger correlation between BPE and FPB in our study
unfortunately suggests that many biopsies are still performed
due to BPE. Nevertheless, neither BPE nor FGT is predictive
of false-positive recalls or biopsies in subsequent screening
rounds, which could mean that BPE and FGT are only affect-
ing false positives when no prior exams are available.
The automated algorithm for BPE estimation eliminates
intra- and interrater variability. This is relevant as previous
studies reported only a fair interrater variability for BPE when
using observer scores according to the BI-RADS lexicon [18].
The automated method provides quantitative measurements
and therefore creates an opportunity to define more precise
cutoff points. The chosen cutoff was selected based upon pre-
vious research, but it is possible that different cutoff points
might lead to different results, but did not lead to different
conclusions. This is in line with a recent study on the prog-
nostic value of BPE in the contralateral breast of women with
unilateral breast cancer, where the effect of different cutoffs
appeared to be minimal [39]. Nevertheless, it should be noted
that the different methods to assess BPE may also lead to
different outcomes in the risk model.
Our study has some limitations. Due to the retrospective
nature of our data, it was not always possible to retrieve data
on the menstrual cycle or menopausal status. Therefore, we
could not correct for these factors. Obviously, menopausal state
is partly covered by including age in the risk model. However,
future research is needed to better investigate the influence of
menopausal status on the predictive value of FGT and BPE for
future breast cancer occurrence. In addition, this was a single-
institutional study, which potentially limits its generalizability.
We chose to include all cancers that were detected in the period
after the baseline scan to find a relation between the baseline
scan and any future breast cancer occurrence (in on average
3 years follow-up). However, relative risks for a shorter period
of time might also be very interesting to study. In addition,
changes of FGT and BPE from the baseline might also be
predictive of risk. As our cohort is too small to answer these
questions, this needs further evaluation in a future study.
During the study period, we changed from a 1.5- to a 3-T
scanner, and also adapted scanning protocols several times
which could potentially influence the results of the BPE calcu-
lation algorithm. However, we ensured that BPE was measured
between 90 and 120 s after contrast administration, and since
BPE is evaluated only semi-quantitatively (in order to imitate
the visual inspection by radiologists), we aimed to minimize
this effect. Still, further standardization of imaging parameters
may improve homogeneity of FGT and BPE estimations and
potentially improve the predictive potential. Another possible
limitation of the study was that only in the case of false-positive
findings did we not exclude women who had a false-positive
finding directly after the first screening round. In theory, this
could alter FGT and BPE scores, although we minimized this
effect by averaging scores over two breasts.
In conclusion, automatically computed FGTand BPE mea-
sures at baseline were not associated with subsequent breast
cancer occurrence in a cohort of women at high risk for breast
cancer. This has implications for personalized screening, as
4688 Eur Radiol (2019) 29:4678–4690
FGT and BPE cannot be implemented in risk prediction
models. Higher FGTand BPE were, however, associated with
higher rates of false-positive findings at baseline; patient
counseling should therefore include these outcomes before
starting MRI screening.
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